Pedersen, Karen Boje
Novo Nordisk (Denmark)
2 papers on CoChat
Most cited papers
- Verified
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 594
- Verified
Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial.
Zinman, B., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., Araki, E., PIONEER 8 Investigators, et al. (2019) · Diabetes Care
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 300
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free